Compares two magnetic brain stimulation devices for teen depression
Compares two deep magnetic stimulation coils in adolescents with major depression.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of DTMS in Adolescent Major Depressive Disorder
Key facts
- Where
- Taiyuan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 11 and 23 years old?
Source: NCT06728280, who can take part
Where in China
- Deep Transcranial Magnetic StimulationTaiyuan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhifen Liu
- Trial code
- NCT06728280
- Record updated
- 12 March 2025
- Original description
The goal of this randomized controlled trial is to explore the efficacy and safety of two different dTMS devices in adolescent depression: deep TMS H1 coil and deep TMS H7 coil.Read full original descriptionShow less
Efficacy and Safety of Deep Transcranial Magnetic Stimulation in Adolescent Major Depressive Disorder: a Prospective Double-Blind Randomized Controlled Trial
The goal of this randomized controlled trial is to explore the efficacy and safety of two different dTMS devices in adolescent depression: deep TMS H1 coil and deep TMS H7 coil.
The main questions it aims to answer are:
Type of study: Clinical trial. Participant population: Adolescents with major depressive disorder (MDD). Objective: To explore whether the H7 coil is no less effective than the H1 coil for adolescents with MDD, further providing clinicians with additional treatment options for patients.
Inclusion: Patients of all genders, aged between 11 and 23 years old, and right-handedness; In accordance with the diagnostic criteria for the major depressive disorder of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (M.I.N.I); Beck Depression Inventory, Second Edition (BDI-II): total BDI-II score> 13 at screening; Subjects who can understand and are willing to strictly follow the clinical trial protocol to complete this study and sign informed consent.
Exclusion: Have obvious suicide risk, or have actual suicide behavior within 6 months before the screening; History of treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial Direct Current Stimulation (tDCS), or transcranial Alternating Current Stimulation (tACS) treatments for any disorders; Participation in any investigational drug trial within 6 months before the baseline visit; A diagnosis of other psychiatric disorders in the DSM-5; History of significant neurologic disease, including subdural hematoma, brain tumor, unexpected seizure/epilepsy disorder, or history of significant head trauma; Other conditions that are not suitable for the study object in the researcher's judgment; Clinically significant laboratory abnormality or medical condition, that in the opinion of the investigator would hinder the subject in completing the procedures required by the study; There are contraindications to magnetic resonance imaging (MRI) scanning or TMS treatment, such as metal or electronic instruments.